---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-069382"
form_type: "8-K"
ticker: null
cik: "0001850838"
company_name: "Omega Therapeutics, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T15:05:29.956316+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Omega Therapeutics amends bylaws to adopt universal proxy rules and enhance stockholder proposal procedures

## Summary
- Amended bylaws require compliance with SEC Rule 14a-19 universal proxy rules for director nominations.
- Enhanced disclosure requirements for stockholder director nominations and business proposals at meetings.
- Stockholders soliciting proxies must use a proxy card color other than white.
- Obsolete provisions deleted; technical and clarifying changes made.

## SEC filing metadata
- accession: 0000950170-23-069382
- form_type: 8-K
- cik: 0001850838
- company_name: Omega Therapeutics, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850838/000095017023069382/0000950170-23-069382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850838/000095017023069382/omga-20231211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-069382
- JSON: https://secwatch.observer/filing/0000950170-23-069382.json
- Plain text: https://secwatch.observer/filing/0000950170-23-069382.txt

## Key facts
- Governance Changes
  Omega Therapeutics, Inc.: On December 7, 2023, the Board of Directors approved amendments to the Company's Amended and Restated Bylaws, addressing universal proxy rules, streamlining stockholder nomination procedures, and making other technical updates (effective 2023-12-07).
  - Change: bylaw amendment
  - Effective: 2023-12-07
  source text: On December 7, 2023, the Board of Directors (the “ Board ”) of Omega Therapeutics, Inc., a Delaware corporation (the “ Company ”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “ Amended and Restated Bylaws ”), which became effective the same day.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850838/000095017023069382/0000950170-23-069382-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.